Interethnic variability of plasma paraoxonase (PON1) activity towards organophosphates and PON1 polymorphisms among Asian populations: a short review

  • MOHAMED ALI Safiyya
    Centre for Molecular Epidemiology, National University of Singapore
  • CHIA Sin Eng
    Centre for Molecular Epidemiology, National University of Singapore Department of Community, Occupational and Family Medicine, National University of Singapore

書誌事項

タイトル別名
  • Interethnic Variability of Plasma Paraoxonase (PON1) Activity towards Organophosphates and PON1 Polymorphisms among Asian Populations━A Short Review

この論文をさがす

抄録

Organophosphate (OP) poisoning is a progressively worrying phenomenon as worldwide pesticide production and consumption has doubled. On average, WHO estimates that 3% of agricultural workers in developing Asian countries suffer an episode of pesticide poisoning every year. Furthermore, the threat of OP usage in terrorism is existent, as seen by the subway tragedy in Tokyo in 1995 where sarin was used. Despite these alarming facts, there is currently no global system to track poisonings related to pesticide use. Human serum paraoxonase (PON1) is the enzyme that hydrolyses OP compounds. Serum PON1 levels and activity vary widely among different ethnic populations. Two commonly studied polymorphisms of PON1 are PON1Q192R and PON1L55M. PON1R192 hydrolyses paraoxon faster than PON1Q192 but hydrolyses diazoxon, sarin and soman eight times slower, and vice versa. PON1M55 has lower plasma levels of PON1 than PON1L55. As the prevalence of the different alleles and genotypic distribution vary between the Asian populations we studied, we propose the necessity to study PON1 polymorphisms and its role in OP toxicity in Asian populations. This would help safeguard the proper care of agricultural workers who might be affected by OP poisoning, and alert relevant anti biological terrorism agencies on possible risks involved in the event of an OP attack and provide effective counter measures.<br>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (51)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ